Shopping Cart
- Remove All
- Your shopping cart is currently empty
EN6-mediated ATP6V1A modification decouples the v-ATPase from the Rags, leading to inhibition of mTORC1 signaling, increased lysosomal acidification and activation of autophagy. EN6 clears TDP-43 aggregates, a causative agent in frontotemporal dementia, in a lysosome-dependent manner. EN6 is a small-molecule in vivo activator of autophagy that covalently targets cysteine 277 in the ATP6V1A subunit of the lysosomal the vacuolar H+ ATPase (v-ATPase).
Pack Size | Price | Availability | Quantity |
---|---|---|---|
1 mg | $39 | In Stock | |
5 mg | $80 | In Stock | |
10 mg | $139 | In Stock | |
25 mg | $216 | In Stock | |
50 mg | $278 | In Stock | |
100 mg | $422 | In Stock | |
500 mg | $957 | In Stock | |
1 mL x 10 mM (in DMSO) | $64 | In Stock |
Description | EN6-mediated ATP6V1A modification decouples the v-ATPase from the Rags, leading to inhibition of mTORC1 signaling, increased lysosomal acidification and activation of autophagy. EN6 clears TDP-43 aggregates, a causative agent in frontotemporal dementia, in a lysosome-dependent manner. EN6 is a small-molecule in vivo activator of autophagy that covalently targets cysteine 277 in the ATP6V1A subunit of the lysosomal the vacuolar H+ ATPase (v-ATPase). |
Molecular Weight | 368.34 |
Formula | C19H14F2N4O2 |
Cas No. | 1808714-73-9 |
Smiles | Fc1ccc(NC(=O)c2cnn(c2)-c2ccccc2F)cc1NC(=O)C=C |
Relative Density. | 1.32 g/cm3 (Predicted) |
Storage | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice. | |||||||||||||||||||||||||
Solubility Information | DMSO: 4.63 mg/mL (12.57 mM), Sonication is recommended. Ethanol: 1.10 mg/mL (2.99 mM), Sonication and heating to 60℃ are recommended. | |||||||||||||||||||||||||
Solution Preparation Table | ||||||||||||||||||||||||||
Ethanol/DMSO
DMSO
|
Copyright © 2015-2024 TargetMol Chemicals Inc. All Rights Reserved.